US2008221184A1PendingUtilityA1

Combined agents for treatment of glaucoma

60
Assignee: SANKYO COPriority: Dec 1, 1999Filed: Oct 23, 2007Published: Sep 11, 2008
Est. expiryDec 1, 2019(expired)· nominal 20-yr term from priority
Inventors:Tomihisa Yokoyama
A61P 9/12A61P 43/00A61K 31/44A61P 27/06A61K 31/41A61K 31/55A61K 45/06A61K 31/557A61K 31/415A61K 31/535A61K 31/4439
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition for the treatment of glaucoma which comprises an angiotensin II antagonist and a prostaglandin which is unoprostone or latanoprost, and a method for treatment of glaucoma by administering the composition to a patient.

Claims

exact text as granted — not AI-modified
1 . A glaucoma treatment pharmaceutical composition for topical, administration to an eye comprising a pharmaceutically effective amount of a combination of (i) an angiotensin II antagonist, wherein said angiotensin II antagonist is a compound of the following formula (I) or a pharmacologically acceptable salt or ester thereof: 
       
         
           
           
               
               
           
         
       
       wherein R 1  represents the following structural formula (Ia) 
       
         
           
           
               
               
           
         
         and (ii) a prostaglandin selected from the group consisting of isopropyl unoprostone and latanoprost, and optionally (iii) a pharmaceutically acceptable carrier. 
       
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein a ratio of the amounts of the angiotensin II antagonist (i) to the prostaglandin (ii) is 100:1 to 1000:1. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein the prostaglandin is isopropyl unoprostone. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein the prostaglandin is latanoprost. 
     
     
         5 . The pharmaceutical composition according to  claim 3 , wherein a ratio of the amounts of the angiotensin II antagonist to the isopropyl unoprostone is 100:1 to 1000:1. 
     
     
         6 . The pharmaceutical composition according to  claim 4 , wherein a ratio of the amounts of the angiotensin II antagonist to the latanoprost is 100:1 to 1000:1. 
     
     
         7 . The pharmaceutical composition according to  claim 1 , wherein the angiotensin II antagonist is present in a concentration of 0.001 volume % to 10 volume %. 
     
     
         8 . The pharmaceutical composition according to  claim 1 , wherein the angiotensin II antagonist is present in a concentration of 0.01 volume % to 5 volume %. 
     
     
         9 . The pharmaceutical composition according to  claim 1 , wherein the prostaglandin is present in a concentration of 0.001 volume % to 10 volume %. 
     
     
         10 . The pharmaceutical composition according to  claim 1 , wherein the prostaglandin is present in a concentration of 0.01 volume % to 5 volume %. 
     
     
         11 . The pharmaceutical composition according to  claim 4 , wherein the latanoprost is present in an amount of 0.005 wt. %. 
     
     
         12 . A method for treating glaucoma and reducing intraocular pressure comprising topically administering to an eye of a warm blooded animal in need thereof a pharmaceutically effective amount of the pharmaceutical composition according to  claim 1 . 
     
     
         13 . The method according to  claim 12 , wherein the warm blooded animal is a human. 
     
     
         14 . The method according to  claim 13 , wherein a ratio of the amounts of the angiotensin II antagonist (i) to the prostaglandin (ii) is 100:1 to 1000:1. 
     
     
         15 . The method according to  claim 13 , wherein the prostaglandin is isopropyl unoprostone. 
     
     
         16 . The method according to  claim 13 , wherein the prostaglandin is latanoprost. 
     
     
         17 . The method according to  claim 13 , wherein the angiotensin II antagonist is present in a concentration of 0.001 volume % to 10 volume %. 
     
     
         18 . The method according to  claim 13 , wherein the angiotensin II antagonist is present in a concentration of 0.01 volume % to 5 volume %. 
     
     
         19 . The method according to  claim 13 , wherein the prostaglandin is present in a concentration of 0.001 volume % to 10 volume %. 
     
     
         20 . The method according to  claim 13 , wherein the prostaglandin is present in a concentration of 0.01 volume % to 5 volume %. 
     
     
         21 . The method according to  claim 16 , wherein the latanoprost is present in an amount of 0.005 wt %. 
     
     
         22 . A method for treating glaucoma comprising administering to a warm blooded animal a pharmaceutically effective amount of active ingredients, the active ingredients comprising (i) an angiotensin II antagonist, wherein said angiotensin II antagonist is a compound of the following formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof: 
       
         
           
           
               
               
           
         
       
       wherein R 1  represents the following structural formula (Ia) 
       
         
           
           
               
               
           
         
         and (ii) a prostaglandin selected from the group consisting of isopropyl unoprostone and latanoprost, the active ingredients (i) and (ii) being administered simultaneously, separately or successively. 
       
     
     
         23 . The method according to  claim 22 , wherein the warm blooded animal is a human. 
     
     
         24 . The method according to  claim 23 , wherein the prostaglandin is isopropyl unoprostone. 
     
     
         25 . The method according to  claim 23 , wherein the prostaglandin is latanoprost.

Join the waitlist — get patent alerts

Track US2008221184A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.